Eisai Rides High On Expanded Oncology Capabilities, Enters Neglected Disease Foray
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Two days after gaining U.S. FDA approval for its first in-house produced oncology product, Eisai continued its week of "firsts" with the announcement that it is the first Japanese pharmaceutical company to reach a supply agreement with the World Health Organization to combat a neglected tropical disease
You may also be interested in...
Success Hinging On Single Platforms For Kissei, Dainippon Sumitomo, NanoCarrier and Eisai: Japan Earnings Roundup (Part 2)
A look at key products that could determine the year ahead for Japanese pharma.
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training